IMGN Financial Facts

Research and development support: 1.33M
License and milestone fees: 305K
See Full Income Statement

Deferred revenue, net of current portion: 58.97M
Long-term restricted cash: 0
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date 10/24/14 EPS Growth Rate -15.4%
Average EPS % Beat Rate -14.2% Revenue Growth Rate +26.7%
Average % Move 1-Wk after EPS -3.6% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
10/24/14 Q115 N/A-$0.15 N/A N/A$21.8M N/A N/A N/A
8/1/14 Q414 -$0.83-$0.32 -$0.51$5.74M$9.72M N/A Details
4/25/14 Q314 -$0.44-$0.27 -$0.17$6.9M$13.28M = Details
1/31/14 Q214 $0.04-$0.18 +$0.22$30.1M$18.16M = Details
10/25/13 Q114 -$0.13-$0.23 +$0.10$17.2M$12.1M = Details
8/2/13 Q413 -$0.26-$0.30 +$0.04$3.83M$3.44M = Details
4/26/13 Q313 -$0.02-$0.15 +$0.13$25M$11.94M N/A Details
1/25/13 Q213 -$0.29-$0.25 -$0.04$2.6M$6.02M N/A Details